pde5 inhibitors

Cardiovascular endocrinology

Cardiovascular endocrinology

Cardiologists have taught us how to conduct large and rigorous clinical trials, but now cardiologists are using our endocrine tools! The beta-adrenergic signaling or the renin-angiotensin-aldosterone system, and more recently the SGLT2 inhibitors, are examples of how neuroendocrine control is central to cardiovascular function. In 'endocrine hands', we are taking back such tools to reveal the molecular players involved.

Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection

A pandemic outbreak of COVID-19 has been sweeping the world since December. It begins as a respiratory infection that, mainly in men with diabetes or renal impairment, evolves into a systemic disease, with SARDS, progressive endothelial cell damage, abnormal clotting and impaired cardiovascular and liver function. Some clinical trials are testing biological drugs to limit the immune system dysregulation, "cytokines storm", that causes the systemic complications of COVID-19.

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma